Home › Companies › ULTRAGENYX PHARMACEUTICAL INC. › 2024-2025
Compiled from SEC Form N-PX filings and ULTRAGENYX PHARMACEUTICAL INC.’s Form 8-K, filed 2025-05-19 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Explore ULTRAGENYX PHARMACEUTICAL INC. in the interactive database Compare manager voting policies
These tallies are ULTRAGENYX PHARMACEUTICAL INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-05-19 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Matthew K. Fust | 69,816,485 | -- | -- | 11,374,883 | 5,318,239 | Majority: yes |
| Elect Director: Amrit Ray, M.D. | 77,323,215 | -- | -- | 3,868,153 | 5,318,239 | Majority: yes |
| Proposal 2: Approval of the Second A&R 2023 Plan At the Annual Meeting, the Company's stockholders approved the Second A&R 2023 Plan. The votes on Proposal 2 were as follows: | 54,269,114 | 26,890,355 | 31,899 | -- | 5,318,239 | Majority: yes |
| Proposal 3: Ratification of Selection of Independent Registered Accounting Firm At the Annual Meeting, the Company's stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal yea | 84,295,941 | 2,188,722 | 24,894 | -- | -- | Majority: yes |
| Proposal 4: Advisory (Non-Binding) Vote to Approve Executive Compensation At the Annual Meeting, the Company's stockholders voted, on an advisory basis, in favor of a resolution approving the compensation the Company pays to its "named executive officers" as d | 55,098,060 | 26,074,207 | 19,101 | -- | 5,318,239 | Majority: yes |
Source: ULTRAGENYX PHARMACEUTICAL INC., Form 8-K, filed with the SEC on 2025-05-19 — read the filing on EDGAR.
Each item below shows how the 348 asset managers that disclosed a ULTRAGENYX PHARMACEUTICAL INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of ULTRAGENYX PHARMACEUTICAL INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 11 wordings of this item as funds reported it.
68% Majority: yes · of votes cast
ULTRAGENYX PHARMACEUTICAL INC.’s own tally for this item (“Proposal 4: Advisory (Non-Binding) Vote to Approve Executive Compensation At the Annual Meeting, the Company's stockholders voted, on an advisory basis, in favor of a resolution approving the compensation the Company pay”): 55,098,060 for, 26,074,207 against, per its Form 8-K filed 2025-05-19 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 93,903,785 outstanding shares: 59% for, 28% against (86% of the company cast a for/against vote).
The 345 asset managers below cast 69% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,882,080 | 745,185 | 0 | 0 | For |
| T. Rowe Price | 5,580,691 | 89,875 | 0 | 0 | For |
| BlackRock | 5,345,884 | 28,305 | 0 | 0 | For |
| Federated Hermes | 4,099,604 | 0 | 0 | 0 | For |
| State Street | 3,575,665 | 45,582 | 0 | 0 | For |
| SANDS CAPITAL MANAGEMENT, LLC | 2,854,891 | 0 | 0 | 0 | For |
| Fidelity | 2,499,722 | 0 | 0 | 0 | For |
| Clearbridge Investments, LLC | 0 | 2,230,833 | 0 | 0 | Against |
| Wellington | 2,073,296 | 0 | 0 | 0 | For |
| Invesco | 2,047,694 | 0 | 0 | 0 | For |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 0 | 2,001,935 | 0 | 0 | Against |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1,983,682 | 0 | 0 | 0 | For |
| RTW INVESTMENTS, LP | 1,707,402 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,631,693 | 0 | 0 | 0 | For |
| AllianceBernstein | 0 | 1,485,207 | 0 | 0 | Against |
| Rock Springs Capital Management LP | 1,371,091 | 0 | 0 | 0 | For |
| Deep Track Capital, LP | 1,350,000 | 0 | 0 | 0 | For |
| Legg Mason | 0 | 1,319,888 | 0 | 0 | Against |
| PICTET ASSET MANAGEMENT SA | 0 | 1,245,699 | 0 | 0 | Against |
| Point72 | 0 | 1,203,546 | 0 | 0 | Against |
| Charles Schwab | 1,189,873 | 0 | 0 | 0 | For |
| BNP Paribas Asset Management Holding S.A. | 0 | 1,068,334 | 0 | 0 | Against |
| Alyeska Investment Group, L.P. | 0 | 899,044 | 0 | 0 | Against |
| Aberdeen | 0 | 882,338 | 0 | 0 | Against |
| Two Sigma | 0 | 881,261 | 0 | 0 | Against |
Showing the 25 largest of 345 asset managers. See all 345 in the interactive database.
Combines 3 wordings of this item as funds reported it.
67% Majority: yes · of votes cast
ULTRAGENYX PHARMACEUTICAL INC.’s own tally for this item (“Proposal 2: Approval of the Second A&R 2023 Plan At the Annual Meeting, the Company's stockholders approved the Second A&R 2023 Plan. The votes on Proposal 2 were as follows:”): 54,269,114 for, 26,890,355 against, per its Form 8-K filed 2025-05-19 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 93,903,785 outstanding shares: 58% for, 29% against (86% of the company cast a for/against vote).
The 99 asset managers below cast 79% of the shares they voted on this item FOR (26,672,906 for, 6,922,351 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 11,411,531 | 7 | 0 | 0 | For |
| T. Rowe Price | 2,407,537 | 34,900 | 0 | 0 | For |
| BlackRock | 2,349,212 | 0 | 0 | 0 | For |
| Fidelity | 1,573,548 | 597,935 | 0 | 0 | For |
| Federated Hermes | 2,049,800 | 0 | 0 | 0 | For |
| Legg Mason | 1,319,888 | 0 | 0 | 0 | For |
| State Street | 2,256 | 1,173,456 | 0 | 0 | Against |
| Invesco | 959,477 | 0 | 0 | 0 | For |
| ACAP Strategic Fund | 0 | 826,698 | 0 | 0 | Against |
| TOUCHSTONE FUNDS GROUP TRUST | 801,796 | 0 | 0 | 0 | For |
| First Light Asset Management, LLC | 608,456 | 0 | 0 | 0 | For |
| Charles Schwab | 589,558 | 0 | 0 | 0 | For |
| TIAA | 0 | 458,810 | 0 | 0 | Against |
| Aberdeen | 0 | 441,169 | 0 | 0 | Against |
| MFS | 0 | 441,090 | 0 | 0 | Against |
| Putnam | 0 | 346,835 | 0 | 0 | Against |
| AllianceBernstein | 345,774 | 0 | 0 | 0 | For |
| Loomis Sayles | 326,789 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 316,731 | 0 | 0 | 0 | For |
| Goldman Sachs | 0 | 285,943 | 0 | 0 | Against |
| John Hancock | 26,489 | 226,931 | 0 | 0 | Against |
| BNY Mellon | 0 | 245,907 | 0 | 0 | Against |
| Advantage Advisers Xanthus Fund, L.L.C. | 0 | 241,221 | 0 | 0 | Against |
| Brighthouse | 168,874 | 2,227 | 13,308 | 0 | For |
| Principal | 181,774 | 0 | 0 | 0 | For |
Showing the 25 largest of 99 asset managers. See all 99 in the interactive database.
Combines 6 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
ULTRAGENYX PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Amrit Ray, M.D.”): 77,323,215 for, 3,868,153 withheld, per its Form 8-K filed 2025-05-19 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 93,903,785 outstanding shares: 82% for, 4% withheld (86% of the company cast a for/withheld vote).
The 99 asset managers below cast 100% of the shares they voted on this item FOR (31,761,945 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 11,411,537 | 0 | 1 | 0 | For |
| T. Rowe Price | 2,407,537 | 0 | 34,900 | 0 | For |
| BlackRock | 2,349,212 | 0 | 0 | 0 | For |
| Fidelity | 2,171,483 | 0 | 0 | 0 | For |
| Federated Hermes | 2,049,800 | 0 | 0 | 0 | For |
| Legg Mason | 1,319,888 | 0 | 0 | 0 | For |
| State Street | 1,175,712 | 0 | 0 | 0 | For |
| Invesco | 959,477 | 0 | 0 | 0 | For |
| ACAP Strategic Fund | 826,698 | 0 | 0 | 0 | For |
| TOUCHSTONE FUNDS GROUP TRUST | 801,796 | 0 | 0 | 0 | For |
| Charles Schwab | 589,558 | 0 | 0 | 0 | For |
| TIAA | 458,810 | 0 | 0 | 0 | For |
| Aberdeen | 441,169 | 0 | 0 | 0 | For |
| MFS | 441,090 | 0 | 0 | 0 | For |
| Putnam | 346,835 | 0 | 0 | 0 | For |
| AllianceBernstein | 0 | 0 | 345,774 | 0 | Abstain |
| Loomis Sayles | 326,789 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 316,731 | 0 | Abstain |
| Goldman Sachs | 285,943 | 0 | 0 | 0 | For |
| John Hancock | 253,420 | 0 | 0 | 0 | For |
| BNY Mellon | 245,907 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 241,221 | 0 | 0 | 0 | For |
| Brighthouse | 171,101 | 0 | 13,308 | 0 | For |
| Principal | 0 | 0 | 181,774 | 0 | Abstain |
| DRIEHAUS MUTUAL FUNDS | 177,893 | 0 | 0 | 0 | For |
Showing the 25 largest of 99 asset managers. See all 99 in the interactive database.
Combines 5 wordings of this item as funds reported it.
86% Majority: yes · of votes cast
ULTRAGENYX PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Matthew K. Fust”): 69,816,485 for, 11,374,883 withheld, per its Form 8-K filed 2025-05-19 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 93,903,785 outstanding shares: 74% for, 12% withheld (86% of the company cast a for/withheld vote).
The 99 asset managers below cast 100% of the shares they voted on this item FOR (28,706,489 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 11,411,536 | 0 | 2 | 0 | For |
| T. Rowe Price | 2,407,537 | 0 | 34,900 | 0 | For |
| BlackRock | 2,349,212 | 0 | 0 | 0 | For |
| Fidelity | 2,171,483 | 0 | 0 | 0 | For |
| Federated Hermes | 2,049,800 | 0 | 0 | 0 | For |
| Legg Mason | 1,319,888 | 0 | 0 | 0 | For |
| State Street | 3,358 | 0 | 1,172,354 | 0 | Abstain |
| Invesco | 0 | 0 | 959,477 | 0 | Abstain |
| ACAP Strategic Fund | 826,698 | 0 | 0 | 0 | For |
| TOUCHSTONE FUNDS GROUP TRUST | 801,796 | 0 | 0 | 0 | For |
| Charles Schwab | 589,558 | 0 | 0 | 0 | For |
| TIAA | 458,810 | 0 | 0 | 0 | For |
| Aberdeen | 441,169 | 0 | 0 | 0 | For |
| MFS | 0 | 0 | 441,090 | 0 | Abstain |
| Putnam | 346,835 | 0 | 0 | 0 | For |
| AllianceBernstein | 0 | 0 | 345,774 | 0 | Abstain |
| Loomis Sayles | 326,789 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 316,731 | 0 | Abstain |
| Goldman Sachs | 0 | 0 | 285,943 | 0 | Abstain |
| John Hancock | 253,420 | 0 | 0 | 0 | For |
| BNY Mellon | 245,907 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 241,221 | 0 | 0 | 0 | For |
| Brighthouse | 171,101 | 0 | 13,308 | 0 | For |
| Principal | 0 | 0 | 181,774 | 0 | Abstain |
| DRIEHAUS MUTUAL FUNDS | 177,893 | 0 | 0 | 0 | For |
Showing the 25 largest of 99 asset managers. See all 99 in the interactive database.
Combines 4 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
ULTRAGENYX PHARMACEUTICAL INC.’s own tally for this item (“Proposal 3: Ratification of Selection of Independent Registered Accounting Firm At the Annual Meeting, the Company's stockholders ratified the selection of Ernst & Young LLP as the independent registered public accountin”): 84,295,941 for, 2,188,722 against, per its Form 8-K filed 2025-05-19 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 93,903,785 outstanding shares: 90% for, 2% against (92% of the company cast a for/against vote).
The 99 asset managers below cast 99.9% of the shares they voted on this item FOR (33,011,107 for, 12,527 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 11,411,538 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,442,437 | 0 | 0 | 0 | For |
| BlackRock | 2,349,212 | 0 | 0 | 0 | For |
| Fidelity | 2,171,483 | 0 | 0 | 0 | For |
| Federated Hermes | 2,049,800 | 0 | 0 | 0 | For |
| Legg Mason | 1,319,888 | 0 | 0 | 0 | For |
| State Street | 1,175,633 | 79 | 0 | 0 | For |
| Invesco | 959,477 | 0 | 0 | 0 | For |
| ACAP Strategic Fund | 826,698 | 0 | 0 | 0 | For |
| TOUCHSTONE FUNDS GROUP TRUST | 801,796 | 0 | 0 | 0 | For |
| Charles Schwab | 589,558 | 0 | 0 | 0 | For |
| TIAA | 458,810 | 0 | 0 | 0 | For |
| Aberdeen | 441,169 | 0 | 0 | 0 | For |
| MFS | 441,090 | 0 | 0 | 0 | For |
| Putnam | 346,835 | 0 | 0 | 0 | For |
| AllianceBernstein | 345,774 | 0 | 0 | 0 | For |
| Loomis Sayles | 326,789 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 316,731 | 0 | 0 | 0 | For |
| Goldman Sachs | 285,943 | 0 | 0 | 0 | For |
| John Hancock | 253,420 | 0 | 0 | 0 | For |
| BNY Mellon | 245,907 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 241,221 | 0 | 0 | 0 | For |
| Brighthouse | 171,101 | 0 | 13,308 | 0 | For |
| Principal | 181,774 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 177,893 | 0 | 0 | 0 | For |
Showing the 25 largest of 99 asset managers. See all 99 in the interactive database.
0% fund support · no official result
The 3 asset managers below cast 0% of the shares they voted on this item FOR (0 for, 41,029 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| GuideStone | 0 | 35,240 | 0 | 0 | Against |
| Maj Invest Holding A/S | 0 | 3,414 | 0 | 0 | Against |
| RWC Asset Management LLP | 0 | 2,375 | 0 | 0 | Against |
Ranked by the number of ULTRAGENYX PHARMACEUTICAL INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 93,903,785 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 12.38% |
| 2 | T. Rowe Price | 6.04% |
| 3 | BlackRock | 5.72% |
| 4 | Federated Hermes | 4.37% |
| 5 | State Street | 3.86% |
| 6 | SANDS CAPITAL MANAGEMENT, LLC | 3.04% |
| 7 | Fidelity | 2.66% |
| 8 | Clearbridge Investments, LLC | 2.38% |
| 9 | Wellington | 2.21% |
| 10 | Invesco | 2.18% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| Vanguard Group | 10.65% | 13F |
| BlackRock | 6.56% | 13F |
| FMR LLC | 3.57% | 13G |
| Emil D. Kakkis, M.D., Ph.D. | 3.51% | DEF14A |
| T. Rowe Price | 3.43% | 13F |
| State Street | 2.79% | 13F |
| Wellington Management | 2.61% | 13F |
| Geode Capital | 1.75% | 13F |
| Invesco | 1.29% | 13F |
| Point72 | 1.04% | 13F |
Percentages above are of 93,903,785 shares outstanding, as reported by ULTRAGENYX PHARMACEUTICAL INC. on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ULTRAGENYX PHARMACEUTICAL INC.’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At ULTRAGENYX PHARMACEUTICAL INC.'s shareholder meeting held 2025-05-15, in the 2024-2025 proxy season, 348 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,989 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — Advisory (non-binding) vote to approve the compensation of our named executive officers. — FOR was 68% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: ULTRAGENYX PHARMACEUTICAL INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-05-19.
ULTRAGENYX PHARMACEUTICAL INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.